Shanghai Henlius Biotech (2696.HK) Earnings Analysis
Shanghai Henlius Biotech (2696.HK) next reports earnings on 2026-08-25, consensus EPS 0.4965 HKD. Last quarter (2026-03-20) it beat with EPS 0.89 HKD vs 0.612 HKD est (+45.4%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 32.71.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 2696.HK next report earnings?
| Next earnings date | 2026-08-25 |
|---|---|
| Consensus EPS estimate | 0.4965 HKD |
| Revenue estimate | 3.93B |
2696.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-20 | 0.89 HKD | 0.612 HKD | +45.4% | Beat |
| 2025-08-25 | 0.783 HKD | n/a | n/a | n/a |
| 2025-03-24 | 0.383 HKD | n/a | n/a | n/a |
| 2024-12-31 | 0.4249 HKD | n/a | n/a | n/a |
| 2024-11-15 | 0.442 HKD | n/a | n/a | n/a |
| 2024-08-26 | 0.3816 HKD | n/a | n/a | n/a |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
2696.HK valuation and analyst view
| Trailing P/E | 32.71 |
|---|---|
| Trailing EPS | 1.495 HKD |
| Price / book | 6.95 |
| Dividend yield | 0.00% |
| Market cap | 31.58B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Shanghai Henlius Biotech (2696.HK)'s next earnings date?
Shanghai Henlius Biotech is next scheduled to report on 2026-08-25, with a consensus EPS estimate of 0.4965 HKD and revenue estimate of 3.93B.
Did 2696.HK beat earnings last quarter?
In its 2026-03-20 report, 2696.HK posted EPS of 0.89 HKD versus a 0.612 HKD estimate — a beat of 45.4%.
What is 2696.HK's earnings track record?
Over the last 1 reported quarters with consensus data, 2696.HK beat estimates 1 times (100%).
What is 2696.HK's current P/E ratio and EPS?
2696.HK trades at a trailing P/E of 32.71 on trailing EPS of 1.494810532626722 HKD.
What do analysts rate 2696.HK?
2696.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.